MEK1 and MEK2 are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway. Approximately 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation. Here we present the X-ray structures of human MEK1 and MEK2, each determined as a ternary complex with MgATP and an inhibitor to a resolution of 2.4 A and 3.2 A, respectively. The structures reveal that MEK1 and MEK2 each have a unique inhibitor-binding pocket adjacent to the MgATP-binding site. The presence of the potent inhibitor induces several conformational changes in the unphosphorylated MEK1 and MEK2 enzymes that lock them into a closed but catalytically inactive species. Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.
The sequence of the 224 residues of H M G 1 suggests it consists of three domains. We have previously proposed [Cary et al. (1980 Eur. J. Biochern. 131,367-3741 that the A and B domains can fold autonomously and that there is also a small N domain. Several proteases are now found to cut at the end of the B domain (at or close to residue 184). It is shown that the A+B-domain fragment also folds and probably contains all the helix of intact HMG 1. The stability of the B domain is enhanced by the presence of the A domain. The acidic C domain undergoes a coil-+ helix transition on lowering the pH. Several peptides have been prepared by cleavage at tryptophan. Peptide 57-Cterminus contains complete B and C domains but does not fold. In the absence of the A domain the C domain is thus able to destabilise the B domain. It is concluded that the stability of the B domain in HMG 1 is due to interaction with the A domain and the C domain has a separate function from the other domains.The chromosomal proteins high-mobility-group (HMG) 1 and 2 and the equivalent protein HMG T in trout testes, may be involved in the structure of active genes. This idea stems initially from the observation [I, 21 of preferential release on mild digestion of nuclei or chromatin with micrococcal nuclease or DNase I and has been supported by noting a stimulation of transcriptional activity on readdition of HMG 1 and 2 to chromatin previously depleted of these proteins [3]. From the structural point of view HMG1/2 have been designated as DNA unwinding proteins [4] and shown to bind preferentially to single-stranded DNA [4, 51. The present series of structural studies are aimed at elucidating the detailed conformation of the proteins in an attempt to throw light on how they might bind to DNA or chromatin and on what function they perform.The most reasonable proposal to date [l] is that they bind to linker DNA and so displace H1 in a state of chromatin that specifically requires the absence of this histone, i.e. active chromatin. Our earlier study [6] and those of others [7], however, show no conformational resemblance to histone H1. The almost complete sequences of Walker et al.[S] indicated a total of 259 residues in HMG1, including an unbroken sequence of 41 acidic residues close to the C-terminal [9]. The C-terminal region of the H M G 1 sequence has effectively been completed by Dixon and colleagues [lo] from the nucleotide sequence of cloned cDNA. This shows (a) that the total number of residues is probably 224, (b) that the acidic stretch is only 30 residues long and continues right up to the C-terminus of the protein and (c) that the putative cysteine at residue 165 is not present, i.e. there is only one cysteine in the whole molecule. Microheterogeneity at this locus is not excluded, however. For the purposes of this paper, the numbering system of Walker et al. will be used. This puts the C-terminal residue at position 221Abbreviations. HMG, high-mobility group; BPNS-skatole, 2-(2-nitrophenylsulphonyl)-3-methyl-3'-bromoindolenine; SDS, so...
The single cysteine on the cc-subunit of bovine brain S-100a protein has been modified with the thiol specific probe, Acrylodan. When the labelled apoprotein was excited at 380 nm the fluorescence emission maximum was centered at 484 f 2 nm, suggesting that the probe is in a fairly hydrophobic environment. Addition of Ca2+ to the protein caused the emission maximum to undergo a red shift to 504 f 2 nm, implying that the fluorophore is now more exposed to the solvent. Zn2+, when added to the protein, induced only a small perturbation and the emission maximum shifted to 48 1 f 2 nm. Ca2+ was able to perturb the fluorophore in the presence of Zn2+. 2-p-Toluidinylnaphthalene-6-sulfonate (TNS)-labelled cc-subunit when excited at 345 nm exhibited very little fluorescence in the absence of Ca2+. Addition of Ca2+ resulted in an increase in TNS fluorescence accompanied by a blue shift of the emission maximum to 445 f 1 nm indicating that the probe in the presence of Ca2+ moves to a hydrophobic domain. The fact that Ca2+ and Zn2+ can perturb the labelled sulthydryl group in the presence of each other clearly demonstrates that the binding sites for the two metal ions must be different on the m-subunit as well as on the S-IOOa protein.S-100 protein; Ca *+ effect; Znz+ effect; Fluorescence
The brain-specific S-100 protein is a mixture of two predominant components, S-100a and S-100b, with subunit compositions of alpha beta and beta beta respectively. In the present study, the alpha-subunit, isolated from S-100a by using anion-exchange chromatography in the presence of 8 M-urea, was homogeneous by the criteria of SDS/polyacrylamide-gel, urea/SDS/polyacrylamide-gel and non-SDS/polyacrylamide-gel electrophoresis. The alpha-subunit underwent a conformational change upon binding Ca2+ and Zn2+ at pH 7.5, as revealed by u.v. difference spectroscopy, c.d. and fluorescence measurements. Far-u.v. c.d. studies indicated the apparent alpha-helical content to fall when the protein bound either Ca2+ or Zn2+. Addition of Ca2+ to the alpha-subunit resulted in exposing to the solvent the single tryptophan residue and one or more tyrosine and phenylalanine residues. Zn2+ induced only a small conformational change, and among the aromatic chromophores only tyrosine residues were affected to a small extent. Ca2+ was able to bind to the alpha-subunit in the presence of Zn2+, and the two metal-ion-binding sites appeared to be different. When the apoprotein was excited at 280 nm, the fluorescence emission maximum was located at 337 nm. In the presence of Ca2+, the emission maximum occurred at 340 nm and was accompanied by a nearly 25% increase in fluorescence intensity. Fluorescence titration with Ca2+ at pH 7.5 revealed only one class of binding site, with a Kd value of 1.26 X 10(-4) M. The effect of K+ on the protein was slightly antagonistic to that of Ca2+, as indicated by u.v. difference spectroscopy and fluorescence titration.
The potential of an anti-inflammatory peptide (antiflammin 1) to reduce irritation when delivered transdermally by iontophoresis was examined. A model drug irritant, chlorpromazine, was co-delivered with and without antiflammin 1 by iontophoresis to hairless guinea pigs transdermally. Quantitative skin irritation measurements were obtained by monitoring erythema by skin color reflectance with the Minolta Chromameter. Antiflammin 1 delivered by iontophoresis significantly decreased, but did not eliminate, the erythema associated with co-delivery of an irritating drug compound. Lesion formation was also reduced in the presence of antiflammin 1. In vitro flux across hairless guinea pig skin demonstrated no significant differences in flux of the irritant compound in the presence or absence of antiflammin 1. In vivo generation and efflux of the inflammation mediator Prostaglandin E2 increased during 24-h application of irritant and was unchanged in the presence of antiflammin 1. This result is discussed with respect to recent evidence that antiflammins may act on the lipo-oxygenase pathway. In summary, antiflammin 1, an anti-inflammatory peptide, can be delivered transdermally by iontophoresis with retention of its biological activity in vivo.
A typographical error was inadvertently introduced in Figure 1a. The corrected chemical structure is shown below. The authors apologize for any inconvenience this may have caused.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.